161 related articles for article (PubMed ID: 27190374)
61. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
63. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
Gallar P; Ortega O; Gutiérrez M; Muñoz M; Hilara L; Oliet A; Rodríguez I; Giménez E; Vigil A
Nefrologia; 2000; 20(4):355-61. PubMed ID: 11039261
[TBL] [Abstract][Full Text] [Related]
64. The impact of various cycling regimens on phosphorus removal in chronic peritoneal dialysis patients.
Juergensen P; Eras J; McClure B; Kliger AS; Finkelstein FO
Int J Artif Organs; 2005 Dec; 28(12):1219-23. PubMed ID: 16404697
[TBL] [Abstract][Full Text] [Related]
65. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Chiang SS; Chen JB; Yang WC
Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
[TBL] [Abstract][Full Text] [Related]
66. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.
Lopes AA; Tong L; Thumma J; Li Y; Fuller DS; Morgenstern H; Bommer J; Kerr PG; Tentori F; Akiba T; Gillespie BW; Robinson BM; Port FK; Pisoni RL
Am J Kidney Dis; 2012 Jul; 60(1):90-101. PubMed ID: 22385781
[TBL] [Abstract][Full Text] [Related]
67. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial.
Pellicano R; Polkinghorne KR; Kerr PG
Am J Kidney Dis; 2008 Jul; 52(1):93-101. PubMed ID: 18423807
[TBL] [Abstract][Full Text] [Related]
68. Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in peritoneal dialysis.
Bernardo AP; Contesse SA; Bajo MA; Rodrigues A; Del Peso G; Ossorio M; Cabrita A; Selgas R
Clin J Am Soc Nephrol; 2011 Mar; 6(3):591-7. PubMed ID: 21115631
[TBL] [Abstract][Full Text] [Related]
69. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Shigematsu T;
Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
[TBL] [Abstract][Full Text] [Related]
70. The impact of blood flow rate on dialysis dose and phosphate removal in hemodialysis patients.
Rafik H; Aatif T; El Kabbaj D
Saudi J Kidney Dis Transpl; 2018; 29(4):872-878. PubMed ID: 30152424
[TBL] [Abstract][Full Text] [Related]
71. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration.
Leypoldt JK
Semin Dial; 2005; 18(5):401-8. PubMed ID: 16191181
[TBL] [Abstract][Full Text] [Related]
72. Precise Quantitative Assessment of the Clinical Performances of Two High-Flux Polysulfone Hemodialyzers in Hemodialysis: Validation of a Blood-Based Simple Kinetic Model Versus Direct Dialysis Quantification.
Lim PS; Lin Y; Chen M; Xu X; Shi Y; Bowry S; Canaud B
Artif Organs; 2018 May; 42(5):E55-E66. PubMed ID: 29193165
[TBL] [Abstract][Full Text] [Related]
73. Performance of hemodialysis with novel medium cut-off dialyzers.
Kirsch AH; Lyko R; Nilsson LG; Beck W; Amdahl M; Lechner P; Schneider A; Wanner C; Rosenkranz AR; Krieter DH
Nephrol Dial Transplant; 2017 Jan; 32(1):165-172. PubMed ID: 27587605
[TBL] [Abstract][Full Text] [Related]
74. Phosphate kinetics during different dialysis modalities.
Ratanarat R; Brendolan A; Volker G; Bonello M; Salvatori G; Andrikos E; Yavuz A; Crepaldi C; Ronco C
Blood Purif; 2005; 23(1):83-90. PubMed ID: 15627742
[TBL] [Abstract][Full Text] [Related]
75. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
[TBL] [Abstract][Full Text] [Related]
76. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders.
Sherman RA
Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681
[TBL] [Abstract][Full Text] [Related]
77. The effects of intradialytic exercise on hemodialysis adequacy: A systematic review.
Kirkman DL; Scott M; Kidd J; Macdonald JH
Semin Dial; 2019 Jul; 32(4):368-378. PubMed ID: 30968465
[TBL] [Abstract][Full Text] [Related]
78. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
79. Dialysate calcium concentration and mineral metabolism in long and long-frequent hemodialysis: a systematic review and meta-analysis for a Canadian Society of Nephrology clinical practice guideline.
Zimmerman DL; Nesrallah GE; Chan CT; Copland M; Komenda P; McFarlane PA; Gangji A; Lindsay R; MacRae J; Pauly RP; Perkins DN; Pierratos A; Rioux JP; Steele A; Suri RS; Mustafa RA
Am J Kidney Dis; 2013 Jul; 62(1):97-111. PubMed ID: 23591289
[TBL] [Abstract][Full Text] [Related]
80. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
Finn WF;
Clin Nephrol; 2006 Mar; 65(3):191-202. PubMed ID: 16550750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
